198 related articles for article (PubMed ID: 19789704)
1. Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer.
Chen Z; Feng J; Buzin CH; Liu Q; Weiss L; Kernstine K; Somlo G; Sommer SS
PLoS One; 2009 Sep; 4(9):e7220. PubMed ID: 19789704
[TBL] [Abstract][Full Text] [Related]
2. Detection of ultrarare somatic mutation in the human TP53 gene by bidirectional pyrophosphorolysis-activated polymerization allele-specific amplification.
Shi J; Liu Q; Sommer SS
Hum Mutat; 2007 Feb; 28(2):131-6. PubMed ID: 17041903
[TBL] [Abstract][Full Text] [Related]
3. Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells.
Khoo BL; Warkiani ME; Tan DS; Bhagat AA; Irwin D; Lau DP; Lim AS; Lim KH; Krisna SS; Lim WT; Yap YS; Lee SC; Soo RA; Han J; Lim CT
PLoS One; 2014; 9(7):e99409. PubMed ID: 24999991
[TBL] [Abstract][Full Text] [Related]
4. PAP: detection of ultra rare mutations depends on P* oligonucleotides: "sleeping beauties" awakened by the kiss of pyrophosphorolysis.
Liu Q; Sommer SS
Hum Mutat; 2004 May; 23(5):426-36. PubMed ID: 15108273
[TBL] [Abstract][Full Text] [Related]
5. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.
Markou A; Farkona S; Schiza C; Efstathiou T; Kounelis S; Malamos N; Georgoulias V; Lianidou E
Clin Cancer Res; 2014 Nov; 20(22):5823-34. PubMed ID: 25398847
[TBL] [Abstract][Full Text] [Related]
6. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
[TBL] [Abstract][Full Text] [Related]
7. Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients.
Breitenbuecher F; Hoffarth S; Worm K; Cortes-Incio D; Gauler TC; Köhler J; Herold T; Schmid KW; Freitag L; Kasper S; Schuler M
PLoS One; 2014; 9(1):e85350. PubMed ID: 24465542
[TBL] [Abstract][Full Text] [Related]
8. Detection of extremely rare alleles by bidirectional pyrophosphorolysis-activated polymerization allele-specific amplification (Bi-PAP-A): measurement of mutation load in mammalian tissues.
Liu Q; Sommer SS
Biotechniques; 2004 Jan; 36(1):156-66. PubMed ID: 14740499
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumor cells and plasma DNA analysis in patients with indeterminate early or metastatic breast cancer.
Shaw JA; Brown J; Coombes RC; Jacob J; Payne R; Lee B; Page K; Hava N; Stebbing J
Biomark Med; 2011 Feb; 5(1):87-91. PubMed ID: 21319970
[TBL] [Abstract][Full Text] [Related]
10. Detection of mutations in EGFR in circulating lung-cancer cells.
Maheswaran S; Sequist LV; Nagrath S; Ulkus L; Brannigan B; Collura CV; Inserra E; Diederichs S; Iafrate AJ; Bell DW; Digumarthy S; Muzikansky A; Irimia D; Settleman J; Tompkins RG; Lynch TJ; Toner M; Haber DA
N Engl J Med; 2008 Jul; 359(4):366-77. PubMed ID: 18596266
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.
Borràs E; Jurado I; Hernan I; Gamundi MJ; Dias M; Martí I; Mañé B; Arcusa A; Agúndez JA; Blanca M; Carballo M
BMC Cancer; 2011 Sep; 11():406. PubMed ID: 21943394
[TBL] [Abstract][Full Text] [Related]
12. The dynamic range of circulating tumor DNA in metastatic breast cancer.
Heidary M; Auer M; Ulz P; Heitzer E; Petru E; Gasch C; Riethdorf S; Mauermann O; Lafer I; Pristauz G; Lax S; Pantel K; Geigl JB; Speicher MR
Breast Cancer Res; 2014 Aug; 16(4):421. PubMed ID: 25107527
[TBL] [Abstract][Full Text] [Related]
13. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
14. Real-time bidirectional pyrophosphorolysis-activated polymerization for quantitative detection of somatic mutations.
Song N; Zhong X; Li Q
PLoS One; 2014; 9(4):e96420. PubMed ID: 24769870
[TBL] [Abstract][Full Text] [Related]
15. Detection of cytokeratin 19, human mammaglobin, and carcinoembryonic antigen-positive circulating tumor cells by three-marker reverse transcription-PCR assay and its relation to clinical outcome in early breast cancer.
Chen Y; Zou TN; Wu ZP; Zhou YC; Gu YL; Liu X; Jin CG; Wang XC
Int J Biol Markers; 2010; 25(2):59-68. PubMed ID: 20586026
[TBL] [Abstract][Full Text] [Related]
16. [Detection of EGFR gene mutations in 100 non-small cell lung cancer clinical samples by a real-time polymerase chain reaction method using amplification refractory mutation system specific primers and Taqman fluorescence probes].
Zhao J; Zhao J; Zhao X; Chen W; Zhong W; Zhang L; Li L; Wang M
Zhongguo Fei Ai Za Zhi; 2013 Jan; 16(1):25-32. PubMed ID: 23327870
[TBL] [Abstract][Full Text] [Related]
17. Identification of Somatically Acquired
Vidula N; Dubash T; Lawrence MS; Simoneau A; Niemierko A; Blouch E; Nagy B; Roh W; Chirn B; Reeves BA; Malvarosa G; Lennerz J; Isakoff SJ; Juric D; Micalizzi D; Wander S; Spring L; Moy B; Shannon K; Younger J; Lanman R; Toner M; Iafrate AJ; Getz G; Zou L; Ellisen LW; Maheswaran S; Haber DA; Bardia A
Clin Cancer Res; 2020 Sep; 26(18):4852-4862. PubMed ID: 32571788
[TBL] [Abstract][Full Text] [Related]
18. Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.
Rothé F; Laes JF; Lambrechts D; Smeets D; Vincent D; Maetens M; Fumagalli D; Michiels S; Drisis S; Moerman C; Detiffe JP; Larsimont D; Awada A; Piccart M; Sotiriou C; Ignatiadis M
Ann Oncol; 2014 Oct; 25(10):1959-1965. PubMed ID: 25185240
[TBL] [Abstract][Full Text] [Related]
19. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
[TBL] [Abstract][Full Text] [Related]
20. Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.
Sueoka-Aragane N; Katakami N; Satouchi M; Yokota S; Aoe K; Iwanaga K; Otsuka K; Morita S; Kimura S; Negoro S;
Cancer Sci; 2016 Feb; 107(2):162-7. PubMed ID: 26577492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
